Compare TNC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | KURA |
|---|---|---|
| Founded | 1870 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1994 | 2015 |
| Metric | TNC | KURA |
|---|---|---|
| Price | $67.59 | $11.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $79.00 | $25.56 |
| AVG Volume (30 Days) | 156.6K | ★ 2.0M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $1,137,600,000.00 | $67,482,000.00 |
| Revenue This Year | $5.77 | $28.28 |
| Revenue Next Year | $4.95 | $106.37 |
| P/E Ratio | $148.02 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $60.18 | $7.36 |
| 52 Week High | $91.93 | $13.90 |
| Indicator | TNC | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 34.81 | 49.64 |
| Support Level | $64.88 | $8.45 |
| Resistance Level | $88.96 | $12.22 |
| Average True Range (ATR) | 2.20 | 0.48 |
| MACD | 0.09 | -0.20 |
| Stochastic Oscillator | 9.62 | 29.98 |
Tennant Co is engaged in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, and asset management solutions. Its products are used in many types of environments, including retail establishments, distribution centers, factories and warehouses, public venues such as arenas and stadiums, office buildings, schools, and more.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.